Recent Updates
Recently added Catalysts

Applied Therapeutics, Inc.

APLT
Richly ValuedPharma · Clinical
FDA catalysts, PDUFA dates & pipeline intelligence
$0.1
▼ 0 · -0.58%

Last traded Feb 2, 2026. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full APLT financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.0952W HIGH $1.50
Volume
2.70 M
Value Traded
282.10 K
Short % Float
1.11%
+3%Week
+3%1 Month
-89.7%3 Month
-78.54%6 Month
-99.63%5 Year
-98.72%All Time

Cash Data

Unlock APLT cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
14.86 M
EPS (TTM)
-0.10
P/E Ratio
-
Ent. Value
5.42 M
Total Shares
144.32 M
Float Shares
131.33 M
Insiders
5.69%
Institutions
59.79%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
PDUFA
2026
Example Drug
Treatment for example condition requiring FDA review
Phase 3Small MoleculeOncology-
Unlock every APLT catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

APLT Catalyst Timeline

Dated clinical, regulatory and corporate events for Applied Therapeutics, Inc.

Unlock the full APLT catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How APLT actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-31Govorestat (AT-007) NDA Submission NDA
Unlock 1 more APLT historical catalyst
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

D26 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.1x
rNPV / MCap
Applied Therapeutics, Inc. faces pipeline headwinds (26/100), with $353M risk-adjusted pipeline value, led by AT-007 in Hereditary Neuropathy Caused by SORD Deficiency (Phase 2), but cash runway is a concern.
Showing 1 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
AT-007 Small moleculeCompletedNCT04117711Classic GalactosemiaPhase 2 COMPLETED 161Dec 14, 2021
Unlock the APLT pipeline intelligence model
Every scored asset with PTRS, rNPV, enrollment velocity and trial design quality.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every APLT program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
govorestat
Priority
CMT-SORDPhase 2/32025-05-1837% (p=0.005) reduction of sorbitol in the sciatic nerve; statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months; statistically significant improvement in CMT-HI; statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 monthsRead MoreApplied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual MeetingRead More
Scroll for more · summaries link to the source press release
Unlock every APLT trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock APLT insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Kanter Stacy J.DirectorSell -43,000 65,000 held$0.11 12/16/2025
Unlock the full APLT insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in APLT

Fund % of Portfolio Current MV Shares Owned Activity
TANG CAPITAL MANAGEMENT LLC 0 % (-100 %) 755.00 K 2.43 M
Unlock every fund holding APLT
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in APLT
Shares held by hedge funds each quarter, and who bought or sold.

APLT Institutional Ownership Trends

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock APLT option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live APLT option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock APLT options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How APLT ranks across every disease it competes in

Competitive Position is a premium feature
See how APLT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

APLT News

About Applied Therapeutics, Inc.

Founded14-05-2019
BIOPHARMAWATCH ELITE PLUS
Trade the next APLT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime